- Home
- SATX vs AVTX Comparison
SATX vs AVTX Comparison
Compare SATX & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SATX
- AVTX
- Stock Information
- Founded
- SATX 2012
- AVTX 2011
- Country
- SATX Israel
- AVTX United States
- Employees
- SATX N/A
- AVTX N/A
- Industry
- SATX Radio And Television Broadcasting And Communications Equipment
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- SATX Technology
- AVTX Health Care
- Exchange
- SATX Nasdaq
- AVTX Nasdaq
- Market Cap
- SATX 177.6M
- AVTX 57.4M
- IPO Year
- SATX N/A
- AVTX 2015
- Fundamental
- Price
- SATX $2.04
- AVTX $4.35
- Analyst Decision
- SATX Strong Buy
- AVTX Strong Buy
- Analyst Count
- SATX 2
- AVTX 6
- Target Price
- SATX $2.25
- AVTX $34.20
- AVG Volume (30 Days)
- SATX 406.1K
- AVTX 67.7K
- Earning Date
- SATX 05-22-2025
- AVTX 05-20-2025
- Dividend Yield
- SATX N/A
- AVTX N/A
- EPS Growth
- SATX N/A
- AVTX N/A
- EPS
- SATX N/A
- AVTX N/A
- Revenue
- SATX $20,648,000.00
- AVTX $441,000.00
- Revenue This Year
- SATX $50.67
- AVTX N/A
- Revenue Next Year
- SATX $1.64
- AVTX N/A
- P/E Ratio
- SATX N/A
- AVTX N/A
- Revenue Growth
- SATX 92.43
- AVTX N/A
- 52 Week Low
- SATX $0.53
- AVTX $4.15
- 52 Week High
- SATX $2.39
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- SATX 65.56
- AVTX 32.20
- Support Level
- SATX $1.99
- AVTX $4.80
- Resistance Level
- SATX $2.02
- AVTX $5.26
- Average True Range (ATR)
- SATX 0.03
- AVTX 0.47
- MACD
- SATX -0.02
- AVTX 0.05
- Stochastic Oscillator
- SATX 87.50
- AVTX 15.15
About SATX SatixFy Communications Ltd.
SatixFy Communications Ltd is engaged in developing end-to-end next-generation satellite communication systems. This includes satellite payloads, user terminals, and modems, which are built on powerful in-house designed chipsets. Their products feature modems equipped with Software Defined Radio and Fully Electronically Steered Multi Beam Antennas that support the entire DVB-RCS2 / DVB-S2X industry standards as well as a complete SDR for any other waveform. The company has a geographical presence in the U.S. & Canada, the UK, and Other countries, with the majority of its revenue generated from the U.S. and Canada.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).